Matching trials
2,411 results
- Modulation of Human Myocardial Metabolism by GLP-1 Dose Response: Complete Statistical AnalysisIndependent statistical analysis of Modulation of Human Myocardial Metabolism by GLP-1 Dose Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01607450).
- Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics: Complete Statistical AnalysisIndependent statistical analysis of Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00605904).
- Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG): Complete Statistical AnalysisIndependent statistical analysis of Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01182350).
- MONARCH 1Independent statistical analysis of MONARCH 1 (NCT02102490), a phase 2 single-group study of abemaciclib in participants with previously treated metastatic breast cancer, including trial design, endpoints, planned statistical analysis, interpretation, and limitations.
- MONARCH 1Independent statistical analysis of A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00549328).
- Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin: Complete Statistical AnalysisIndependent statistical analysis of Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Morpheus LungIndependent statistical analysis of A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer): primary endpoint results, effect estimate with confidence interval,…
- MOTIONIndependent statistical analysis of A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- MOUNTAINEERIndependent statistical analysis of the phase 2 MOUNTAINEER trial of tucatinib plus trastuzumab in patients with HER2-positive metastatic colorectal adenocarcinoma, including trial design, cORR methodology, safety, and statistical interpretation.
- MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…
- Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination: Complete Statistical AnalysisIndependent statistical analysis of Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04722003).
- Multi OIT to Test Immune Markers After Minimum Maintenance Dose: Complete Statistical AnalysisIndependent statistical analysis of Multi OIT to Test Immune Markers After Minimum Maintenance Dose: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03181009).
- Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.: Complete Statistical AnalysisIndependent statistical analysis of Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint…
- Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy: primary endpoint results, effect estimate with confidence interval,…
- Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant: Complete Statistical AnalysisIndependent statistical analysis of Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant: Complete Statistical AnalysisIndependent statistical analysis of Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery: Complete Statistical AnalysisIndependent statistical analysis of Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy: Complete Statistical AnalysisIndependent statistical analysis of Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01677377).
- Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698: Complete Statistical AnalysisIndependent statistical analysis of Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Musculoskeletal Effects of Bicarbonate: Complete Statistical AnalysisIndependent statistical analysis of Musculoskeletal Effects of Bicarbonate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01475214).
- MUSICIndependent statistical analysis of Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04484935).
- MVP#1Independent statistical analysis of Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00515177).
- My-CRAIndependent statistical analysis of Oral Liquid 13-cis-retinoic Acid (13-CRA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03291080).
- MYCureIndependent statistical analysis of Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft: Complete Statistical AnalysisIndependent statistical analysis of Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- N-Acetyl Cysteine in Pathologic Skin Picking: Complete Statistical AnalysisIndependent statistical analysis of N-Acetyl Cysteine in Pathologic Skin Picking: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01063348).
- N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC): Complete Statistical AnalysisIndependent statistical analysis of N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03759639).
- Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA: Complete Statistical AnalysisIndependent statistical analysis of Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01893801).
- Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence…
- Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: primary endpoint results, effect estimate with…
- Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas: Complete Statistical AnalysisIndependent statistical analysis of Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nabilone in Cannabis Users With PTSD: Complete Statistical AnalysisIndependent statistical analysis of Nabilone in Cannabis Users With PTSD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03251326).
- NACIndependent statistical analysis of Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NACIndependent statistical analysis of N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02791945).
- NAC MJ PilotIndependent statistical analysis of An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00542750).
- NAD+ Precursor Supplementation in Friedreich’s Ataxia: Complete Statistical AnalysisIndependent statistical analysis of NAD+ Precursor Supplementation in Friedreich's Ataxia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04817111).
- NADIMIndependent statistical analysis of the NADIM II phase 2 randomized trial evaluating neo-adjuvant immunotherapy with nivolumab plus chemotherapy in non small cell lung cancer.
- Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NARLALIndependent statistical analysis of Navelbine And Radiotherapy in Locally Advanced Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00887783).
- Nasal Tea Tree Oil for the Prevention of Infections in PD Patients: Complete Statistical AnalysisIndependent statistical analysis of Nasal Tea Tree Oil for the Prevention of Infections in PD Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NASH-CXIndependent statistical analysis of Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis: primary endpoint results,…
- Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I – II Trial: Complete Statistical AnalysisIndependent statistical analysis of Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- NAVIGATEAn educational statistical analysis of the phase 2 NAVIGATE trial of larotrectinib in adults and children with NTRK-fusion positive solid tumors, covering its nonrandomized multi-arm design, response endpoint, statistical methodology, and interpretation.
- NavigatorIndependent statistical analysis of A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3…